REVIEW ARTICLE

DRUG THERAPY

The Medical Management of Depression

J. John Mann, M.D.

Recurrent episodes of major depression, which is a common and serious illness, are called major depressive disorder; depressive episodes that occur in conjunction with manic episodes are called bipolar disorder. Major depressive disorder accounts for 4.4 percent of the total global disease burden, a contribution similar to that of ischemic heart disease or diarrheal diseases. The prevalence of major depressive disorder in the United States is 5.4 to 8.9 percent and of bipolar disorder, 1.7 to 3.7 percent. Major depression affects 5 to 13 percent of medical outpatients, yet is often undiagnosed and untreated. Moreover, it is often undertreated when correctly diagnosed.

The demographics of depression are impressive. Among persons both with major depressive disorder and bipolar disorder, 75 to 85 percent have recurrent episodes. In addition, 10 to 30 percent of persons with a major depressive episode recover incompletely and have persistent, residual depressive symptoms, or dysthymia, a disorder with symptoms that are similar to those of major depression but last longer and are milder. Patients who have diabetes, epilepsy, or ischemic heart disease with concomitant major depression have poorer outcomes than do those without depression. The risk of death from suicide, accidents, heart disease, respiratory disorders, and stroke is higher among the depressed. Effective treatment of depression may reduce mortality or improve the outcome after acute myocardial infarction or stroke and lower the risk of suicide.

The clinical picture of depression varies from one major depressive episode to another in any given patient. This suggests that major depression, despite its various symptom profiles, may have a common underlying cause. If so, the clinically evident symptom profiles may result from differing patterns of neurotransmitter abnormalities in various brain regions. Consonant with such hypotheses, a host of deficiencies — in serotonin, norepinephrine, dopamine, γ-aminobutyric acid (GABA), and peptide neurotransmitters or trophic factors such as brain-derived neurotrophic factor, somatostatin, and thyroid-related hormones — have been proposed as contributing to depression. Furthermore, overactivity in still other neurotransmitter systems involving acetylcholine, corticotropin-releasing factor, and substance P are thought to be implicated in depression. Although no specific abnormalities in genes that control neurotransmitter or hormonal synthesis or release have been identified with certainty, both major depressive disorder and bipolar disorder are clearly heritable. How a genetic predisposition interacts with adverse early-life experience to alter brain development and lead to major depression remains unclear.

Genes and stress are hypothesized to alter neuron size and the extent of neuronal processes, the production of new neurons, and neural repair in major depression.
Elevated cortisol levels, which characterize some moderate-to-severe depressive states, may be associated with a reduction in hippocampal volume, which appears to be proportional to the duration of untreated depression. This process has been likened to a loss of neurons similar to that mediated by corticosteroids in animal models of stress and as suggested by magnetic-resonance-imaging studies that have reported lower levels of N-acetyl aspartate, a neuronal marker, in depression.

Major depression in response to stressful situations has been reported as more common among persons harboring a variant in the proximal 5' regulatory region of the gene encoding the serotonin-transporter protein (5-HTT) (the target of selective serotonin-reuptake inhibitors [SSRIs]) that modifies promoter activity. This variant, in the 5-HTT gene–linked promoter region (5-HTTLPR), modifies promoter activity and is associated with lower transcriptional efficiency of the 5-HTT gene, ultimately leading to fewer copies of the messenger RNA encoding the serotonin-transporter protein. This lower-expressing variant may be associated with the amygdala–mediated hyperresponsiveness of young children to frightened or frightening faces that can facilitate encoding of painful memories, leading to stress sensitivity in adulthood. This variant is also associated with a reduction of serotonin function in response to maternal deprivation in nonhuman primates, an effect that persists into adulthood. An induced functional deficiency of the 5-HTT protein that is confined to the early postnatal period in mice results in altered behavior when they are grown, indicating possible changes in brain development that affect adult behavior.

Brain imaging has identified numerous regions of altered structure or activity in the brain during major depression, suggesting disordered neurocircuitry in a variety of structures, such as the anterior and posterior cingulate cortex; the ventral, medial, and dorsolateral prefrontal cortex; the insula; the ventral striatum; the hippocampus; the medial thalamus; the amygdala; and the brainstem. These brain areas regulate emotional, cognitive, autonomic, sleep, and stress-response behaviors that are impaired in mood disorders. Studies with the use of positron-emission tomography indicate a decrease in serotonin transporters as well as altered postsynaptic serotonin-receptor binding in many of the same brain regions, suggesting altered circuitry congruent with serotonin-system abnormalities.

Diagnosis of major depression is based on standard clinical criteria such as those published by the American Psychiatric Association. The criteria for the diagnosis of an episode include at least two weeks of depressed mood, loss of interest, or diminished sense of pleasure plus four of seven other features that are sufficient to cause clinically important psychological or physical distress or functional impairment. These features include a weight change of 5 percent or more in one month or a persistent change in appetite, insomnia or hypersomnia on most days, changes in psychomotor state, fatigue, feelings of guilt and worthlessness, diminished concentration and decisiveness, and suicidal ideation or a suicide attempt. First or “early” depressive episodes are often milder than are episodes of returning depression, and an earlier age at onset generally predicts a more severe course. It is thought that early diagnosis and treatment may mitigate adverse effects of depression on education, career, and relationships.

It is important to note that secondary depression that is similar to a primary mood disorder may be triggered by serious physical illness such as cancer, stroke, demyelinating diseases, epilepsy, or even marked anemia. Conversely, major depression may be missed when patients present to primary care physicians with predominantly somatic symptoms, including pain. Typically, symptoms such as anorexia, weight loss, constipation, disturbed sleep, anergia, loss of libido, vague aches and pains, and deficiencies in memory and concentration may result in a missed diagnosis, particularly if the patient does not spontaneously report low mood or other psychological symptoms, such as guilt, hopelessness, anxiety, suicidal ideation, or prior suicide attempts. Delusions of guilt and somatic illness complicate up to 14 percent of major depressive episodes, especially postpartum depression.

Depressive episodes in bipolar disorder may be similar to those in major depressive disorder or may present as part of a mixed state characterized by distressing combinations of depression and mania or hypomania (irritability, racing thoughts, anxiety, suicidal thoughts, and aggressive impulses). Patients with bipolar disorder who present with a depressive episode may be misdiagnosed as having major depressive disorder because they may...
About half of moderate-to-severe episodes of depression will improve with antidepressant treatment.\textsuperscript{32} Classes of antidepressant agents are defined by their mechanism of action (Table 1). Many agents with effective antidepressant action amplify serotonin or norepinephrine signaling by inhibiting reuptake at the synaptic cleft (Fig. 1A and 1B). The several classes of drugs include SSRIs, norepinephrine-reuptake inhibitors, and dual-action agents that inhibit uptake of serotonin and norepinephrine. Monoamine oxidase inhibitors (MAOIs) inhibit monoamine degradation by monoamine oxidase A or B. Other antidepressant agents antagonize \( \alpha_2 \)-adrenergic autoreceptors with a resultant increase in the release of norepinephrine, antagonize 5-hydroxytryptamine\(_{2A} \) (5-HT\(_{2A} \)) receptors, or both.

### SSRIs

Clinical trials have shown little difference in efficacy or tolerability among various available SSRIs\textsuperscript{32-34} or between SSRIs and other classes of antidepressants.\textsuperscript{32,35-38} However, some specific differences should be noted.

The active metabolite of fluoxetine has a half-life that is longer than that of other SSRIs, which permits once-daily dosing and thereby reduces the effect of missed doses and mitigates the SSRI discontinuation syndrome (described below). However, fluoxetine should be used with caution in patients with bipolar disorder or a family history of bipolar disorder, because an active metabolite persists for weeks and may aggravate the manic state in the event of a switch from depression to mania. At higher doses, paroxetine and sertraline also block dopamine reuptake, which may contribute to their antidepressant action.

SSRIs can be helpful in patients who do not have a response to tricyclic antidepressants, an older class of drugs, and appear to be better tolerated with lower rates of discontinuation\textsuperscript{32,36,37,39} and fewer cardiovascular effects.\textsuperscript{39} Although tricyclic antidepressants may have greater efficacy than SSRIs in severe major depressive disorder or depression with melancholic features, they are less effective than SSRIs for bipolar depression, since they can trigger mania or hypomania.\textsuperscript{40} SSRIs appear to be less effective than either tricyclic antidepressants or selective norepinephrine-reuptake inhibitors for depression in which physical symptoms or pain is prominent.\textsuperscript{41} The SSRI fluoxetine is the only antidepressant that has consistently been shown to be effective in children and adolescents,\textsuperscript{42} and SSRIs may be superior to selective norepinephrine-reuptake inhibitors in young adults (18 to 24 years of age),\textsuperscript{43} although they are more likely to trigger mania in children.\textsuperscript{44}

### Norepinephrine-reuptake inhibitors

Nortriptyline, maprotiline, and desipramine are tricyclic norepinephrine-reuptake inhibitors with anticholinergic effects.\textsuperscript{45} Reboxetine is a selective norepinephrine-reuptake inhibitor with an effectiveness similar to that of tricyclic antidepressants and SSRIs,\textsuperscript{32} though it is unavailable in the United States.

### Dual-action antidepressants

Serotonin–norepinephrine reuptake inhibitors such as venlafaxine, duloxetine, and milnacipran block monoamine transporters more selectively than tricyclic antidepressants and without the cardiodconduction effects that can occur with tricyclic agents.\textsuperscript{32} Some tricyclics (imipramine and amitriptyline) inhibit both serotonin and norepinephrine reuptake. The dual-action antidepressant venlafaxine appears to demonstrate superior efficacy and higher rates of remission in severe depression as compared with either SSRIs such as fluoxetine or tricyclic antidepressants.\textsuperscript{46-48} The efficacy of duloxetine is similar to that of the SSRI paroxetine.\textsuperscript{49} Venlafaxine and duloxetine are effective for the treatment of chronic pain\textsuperscript{50} and diabetic neuropathic pain, respectively,\textsuperscript{51} as well as pain occurring as part of primary or secondary depression.\textsuperscript{52,53} Bupropion, which inhibits both norepinephrine and dopamine reuptake, has no direct action on the serotoninn system and is generally similar in efficacy to tricyclic antidepressants\textsuperscript{32} and SSRIs.\textsuperscript{54} Bupropion is associated with less nausea, diarrhea, somnolence, and sexual dysfunction than are SSRIs\textsuperscript{54} and constitutes an effective alternative, or adjunctive therapy, for patients who do not have a response to SSRIs.\textsuperscript{55,56}
Table 1. Classification, Doses, Safety, and Side Effects of Antidepressants.*

<table>
<thead>
<tr>
<th>Mechanism of Action and Functional Classification</th>
<th>Starting Dose</th>
<th>Standard Dose</th>
<th>Lethality in Overdose</th>
<th>Insomnia and Agitation</th>
<th>Sedation</th>
<th>Hypotension</th>
<th>Anticholinergic Effects†</th>
<th>Nausea or Gastrointestinal Effects</th>
<th>Sexual Dysfunction</th>
<th>Weight Gain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reuptake inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective serotonin-reuptake inhibitors (SSRIs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoxetine (Prozac)</td>
<td>20</td>
<td>20–40</td>
<td>Low</td>
<td>Moderate</td>
<td>None or mild</td>
<td>None or mild</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Mild</td>
</tr>
<tr>
<td>Paroxetine (Paxil)</td>
<td>20</td>
<td>20–40</td>
<td>Low</td>
<td>Moderate</td>
<td>None or mild</td>
<td>None or mild</td>
<td>Mild</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Mild</td>
</tr>
<tr>
<td>Sertraline (Zoloft)</td>
<td>50</td>
<td>50–150</td>
<td>Low</td>
<td>Moderate</td>
<td>None or mild</td>
<td>None or mild</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Mild</td>
</tr>
<tr>
<td>Fluvoxamine (Luvox)</td>
<td>50</td>
<td>100–250</td>
<td>Low</td>
<td>Moderate</td>
<td>Mild</td>
<td>None or mild</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Mild</td>
</tr>
<tr>
<td>Citalopram (Celexa)</td>
<td>20</td>
<td>20–40</td>
<td>Low</td>
<td>Moderate</td>
<td>None or mild</td>
<td>None or mild</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Mild</td>
</tr>
<tr>
<td>Escitalopram (Lexapro)</td>
<td>10</td>
<td>10–20</td>
<td>Low</td>
<td>Moderate</td>
<td>None or mild</td>
<td>None or mild</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Mild</td>
</tr>
<tr>
<td>Selective norepinephrine-reuptake inhibitors (NRIs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reboxetine (Edronax)‡</td>
<td>4–8</td>
<td>8–12</td>
<td>Low</td>
<td>Mild</td>
<td>None or mild</td>
<td>None or mild</td>
<td>Mild</td>
<td>Mild</td>
<td>None or mild</td>
<td>None or mild</td>
</tr>
<tr>
<td>Nonselective norepinephrine-reuptake inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desipramine (Norpramine)</td>
<td>25–50</td>
<td>100–300</td>
<td>High</td>
<td>Mild</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Mild</td>
<td>None or mild</td>
<td>Mild</td>
<td>Mild</td>
</tr>
<tr>
<td>Nortriptyline (Pamelor)</td>
<td>25–50</td>
<td>75–200</td>
<td>High</td>
<td>Mild</td>
<td>Mild</td>
<td>Mild</td>
<td>Mild</td>
<td>None or mild</td>
<td>Mild</td>
<td>Mild</td>
</tr>
<tr>
<td>Maprotiline (Ludiomil)</td>
<td>75</td>
<td>75–200</td>
<td>High</td>
<td>None or mild</td>
<td>Mild</td>
<td>Mild</td>
<td>Mild</td>
<td>None or mild</td>
<td>Mild</td>
<td>Moderate</td>
</tr>
<tr>
<td>Mixed or dual-action reuptake inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Older agents (TCAs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline (Elavil)</td>
<td>25–50</td>
<td>100–300</td>
<td>High</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Severe</td>
<td>None or mild</td>
<td>Mild</td>
<td>Moderate</td>
</tr>
<tr>
<td>Dothiepin (Dothepl)‡</td>
<td>25–50</td>
<td>100–300</td>
<td>High</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>None or mild</td>
<td>Mild</td>
<td>Moderate</td>
</tr>
<tr>
<td>Clomipramine (Anafranil)</td>
<td>25–50</td>
<td>100–250</td>
<td>High</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Mild</td>
<td>Mild</td>
<td>Moderate</td>
</tr>
<tr>
<td>Imipramine (Tofranil)</td>
<td>25–50</td>
<td>100–300</td>
<td>High</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>None or mild</td>
<td>Mild</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
**Newer agents (non-TCAs)**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Starting Dose</th>
<th>Dose Range</th>
<th>NRI</th>
<th>SRI</th>
<th>MAOI</th>
<th>DRI</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Venlafaxine (Effexor) (NRI plus SRI)</strong></td>
<td>37–75</td>
<td>75–225</td>
<td>Moderate</td>
<td>Moderate</td>
<td>None or mild</td>
<td>None or mild</td>
<td>None or mild</td>
</tr>
<tr>
<td><strong>Milnacipran (Ixel) (NRI plus SRI)</strong>‡</td>
<td>50–100</td>
<td>100–200</td>
<td>Low</td>
<td>Moderate</td>
<td>None or mild</td>
<td>None or mild</td>
<td>Moderate</td>
</tr>
<tr>
<td><strong>Bupropion (Wellbutrin) (NRI plus DRI)</strong></td>
<td>150</td>
<td>150–300</td>
<td>Low</td>
<td>Moderate</td>
<td>None or mild</td>
<td>Mild</td>
<td>Mild</td>
</tr>
<tr>
<td><strong>Duloxetine (Cymbalta) (NRI plus SRI)</strong></td>
<td>30</td>
<td>30–90</td>
<td>Low</td>
<td>None or mild</td>
<td>Mild</td>
<td>None or mild</td>
<td>Mild</td>
</tr>
</tbody>
</table>

**MAOIs**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Starting Dose</th>
<th>Dose Range</th>
<th>NRI</th>
<th>SRI</th>
<th>MAOI</th>
<th>DRI</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phenelzine (Nardil)</strong></td>
<td>15</td>
<td>30–90</td>
<td>High</td>
<td>Moderate</td>
<td>Mild</td>
<td>None or mild</td>
<td>Mild</td>
</tr>
<tr>
<td><strong>Tranylcypromine (Parnate)</strong></td>
<td>10</td>
<td>20–60</td>
<td>High</td>
<td>Moderate</td>
<td>Mild</td>
<td>Moderate</td>
<td>Mild</td>
</tr>
<tr>
<td><strong>Isocarboxazid (Marplan)</strong></td>
<td>20</td>
<td>20–60</td>
<td>High</td>
<td>Moderate</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Mild</td>
</tr>
<tr>
<td><strong>Selegiline (Eldepryl)</strong></td>
<td>10</td>
<td>20–40</td>
<td>Moderate</td>
<td>Mild</td>
<td>None or mild</td>
<td>Mild</td>
<td>Mild</td>
</tr>
</tbody>
</table>

**Mixed-action newer agents**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Starting Dose</th>
<th>Dose Range</th>
<th>NRI</th>
<th>SRI</th>
<th>MAOI</th>
<th>DRI</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mirtazapine (Remeron) (5-HT_2 plus 5-HT_3 plus (\alpha_2)-adrenergic receptors)</strong></td>
<td>30</td>
<td>30–60</td>
<td>Low</td>
<td>None or mild</td>
<td>Severe</td>
<td>Mild</td>
<td>None or mild</td>
</tr>
<tr>
<td><strong>Mianserin (Bolidon) (5-HT_2 plus (\alpha_2)- and (\alpha_3)-adrenergic receptors)</strong>‡</td>
<td>30</td>
<td>60–120</td>
<td>Low</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Mild</td>
<td>Mild</td>
</tr>
<tr>
<td><strong>Nefazodone (Serzone) (5-HT_2 receptors)</strong></td>
<td>100</td>
<td>300–600</td>
<td>Low</td>
<td>None or mild</td>
<td>Moderate</td>
<td>Mild</td>
<td>Mild</td>
</tr>
<tr>
<td><strong>Trazodone (Desyrel) (5-HT_2 plus (\alpha_1)-adrenergic receptors)</strong></td>
<td>50–100</td>
<td>200–600</td>
<td>Low</td>
<td>None or mild</td>
<td>Severe</td>
<td>Mild</td>
<td>None or mild</td>
</tr>
</tbody>
</table>

*These doses are standard in psychiatric practice but may not always conform to doses recommended in the Physician's Desk Reference or drug package insert. More detailed reviews of side effects for all classes of antidepressants may be found in the Guidelines of the American Psychiatric Association 2000 and the Agency for Health Care Policy and Research 1999. NRI denotes norepinephrine-reuptake inhibitor, TCA tricyclic antidepressant, SRI serotonin-reuptake inhibitor, MAOI monoamine oxidase inhibitor, and DRI dopamine-reuptake inhibitor. † Symptoms include dry mouth, constipation, sweating, blurred vision, and urinary retention. ‡ This drug is not available in the United States.
Older, irreversible MAOIs nonselectively block MAO A and B isoenzymes and have an antidepressant efficacy similar to that of tricyclic antidepressants. However, MAOIs are not first-line drugs because patients who receive them must adhere to a low-tyramine diet to prevent hypertensive crisis and because MAOIs carry greater drug-interaction risks than do other medications. MAOIs appear to be superior to tricyclic agents for people with depression characterized by extreme fatigue or extreme psychological sensitivity to rejection or failed relationships. MAOIs are also useful for treating patients who do not have a response to tricyclic antidepressants. The reversible selective MAO A inhibitor moclobemide (which is not available in the United States but widely available in other countries) and the MAO B-selective inhibitor, selegiline, have a greater safety margin than do SSRIs but similar efficacy. A selegiline transdermal patch is under consideration by the Food and Drug Administration (FDA).

Mirtazapine enhances the release of norepinephrine by blocking \( \alpha_2 \)-adrenergic autoreceptors as well as serotonin 5-HT\(_{1A} \) and 5-HT\(_{3} \) receptors and histamine H\(_2 \) receptors. Its efficacy is similar to that of tricyclic antidepressants and SSRIs, and it is less likely to have sexual and sleep-related side effects.

Nefazodone, which blocks the 5-HT\(_{2A} \) serotoni...
nin receptor and serotonin reuptake, has an antidepressant efficacy similar to that of SSRIs but with a lower likelihood of sexual-dysfunction and sleep-related side effects.\textsuperscript{64,65} Nefazodone appears to be useful in postpartum depression,\textsuperscript{66} severe depression,\textsuperscript{67} and treatment-resistant major depression with anxiety.\textsuperscript{68}

New antidepressive treatments currently being evaluated include vagal-nerve stimulation, rapid transcranial magnetic stimulation, mifepristone (a glucocorticoid antagonist for treatment of delusional depression), and substance P antagonists. Other targets for future agents include neuropeptide Y, vasopressin V1b, N-methyl-D-aspartate, nicotinic cholinergic, delta-opiate, cannabinoid, dopamine D1, cytokine, and corticotropin-releasing factor 1 receptors, as well as GABA, intracellular messenger systems, and transcription, neuroprotective, and neurogenic factors.

<table>
<thead>
<tr>
<th>AUGMENTING AND ADJUNCTIVE MEDICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Various medications used in conjunction with other antidepressants may help to augment the effect of antidepressants (Table 2). They can also target different components of patients' symptoms (such as delusions) or help to prevent a switch into mania.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MOOD STABILIZERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lithium is an anionic agent and, as a mood stabilizer, prevents the recurrence of mania or depression. It may be superior to placebo for bipolar depression but not for major depression.\textsuperscript{69} Lithium is an effective augmenting agent, and the condition of roughly half the patients who do not have a response to a single antidepressant improves when lithium is added.\textsuperscript{70,71} The anticonvulsant lamotrigine reduces glutamatergic activity and has been used as an augmenting agent in major depressive disorder\textsuperscript{72} and for treating and preventing depressive relapse in bipolar disorder.\textsuperscript{73} Lamotrigine can induce severe skin reactions, including the Stevens–Johnson syndrome and toxic epidermal necrolysis, although gradual dose titration appears to reduce the risk. Other mood stabilizers, including the anticonvulsants valproic acid, divalproex, and carbamazepine, are used to treat mania in bipolar disorder. Divalproex or valproate may prevent a recurrence of bipolar depression.\textsuperscript{74}</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ANTIPSYCHOTIC AGENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Typical antipsychotic agents (e.g., chlorpromazine, fluphenazine, and haloperidol) block the dopamine D2 receptor, whereas “atypical” antipsychotic agents (e.g., clozapine, olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole), like nefazodone, act as 5HT\textsubscript{2A} antagonists. Antipsychotic drugs are combined with antidepressants to treat depression with psychotic features.\textsuperscript{75,76} Atypical antipsychotic drugs are also used for treatment-resistant major depression\textsuperscript{77} and bipolar depression.\textsuperscript{78} Although atypical antipsychotic drugs have a more favorable side-effect profile with respect to parkinsonism, akathisia, and tardive dyskinesia, some pose other risks, such as drug-induced arrhythmia, diabetes, weight gain, and hyperlipidemia.\textsuperscript{79,80}</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OVERALL THERAPEUTIC STRATEGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients who present with the complex, variable clinical picture of major depressive disorder and bipolar disorder may require a multimodal approach that includes pharmacotherapy, education, and psychotherapy. Treatment requires the monitoring of clinical responses, including suicidal ideation or behavior and side effects. To encourage adherence to therapy, education of both patients and their families must emphasize the fact that the effects of antidepressant medication take time. The average treatment duration for an episode is six months, and there is a high risk of future episodes; thus, both patients and their families must be made aware of these facts. The treatment plan should take into account the patient's previous treatment outcomes, the mood-disorder subtype, the severity of the current episode of depression, the risk of suicide, coexisting psychiatric and somatic conditions, non-psychiatric medications, and psychosocial stressors.\textsuperscript{45} There are three phases of treatment: the acute, continuation, and maintenance phases.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ACUTE PHASE</th>
</tr>
</thead>
<tbody>
<tr>
<td>The treatment goal in the acute phase is remission — the induction of a state with minimal symptoms — in which the criteria for a major depressive episode have abated and marked improvement in psychosocial functioning has occurred, on the basis of reports from the patient and the patient's family. Figure 2 presents a basic algorithm for the acute</td>
</tr>
</tbody>
</table>
The phase of treatment of a major depressive episode in a patient with major depressive disorder, on the basis of the current literature and treatment models, which were developed as part of several large-scale studies of treatment algorithms.

Hospitalization is needed if symptoms are severe (dehydration, delusions, and psychomotor agitation) and there is a risk of suicide (previous suicide attempts or current plan for suicide).

Antidepressants are the treatment of choice for moderate-to-severe episodes of depression. Since most antidepressants that are used for major de-
pressive disorder have similar effectiveness, the choice of medication depends on depressive symptoms (psychotic or suicidal), the history of responses to medication (including that of first-degree relatives), medication tolerability, adverse effects, and the likelihood of adherence. Other considerations are concurrent medical conditions, use of nonpsychiatric drugs, and cost of medication. Table 3 lists suggested first-line medications.

SSRIs and other newer antidepressant drugs with a greater safety margin constitute first-line medications for moderate-to-severe depression, particularly for outpatients, for patients treated by primary care physicians, and for patients with cardiovascular disease. Depression in persons 65 years of age or older generally requires relatively low doses of antidepressants, and SSRIs appear to be preferable to nonselective norepinephrine-reuptake inhibitors, such as tricyclic antidepressants, because of the lower risk of anticholinergic and cardiovascular side effects.

The acute treatment phase usually lasts 6 to 10 weeks (Table 1). The patient should be evaluated weekly or twice monthly by the treating physician until substantial improvement is achieved. Doses should be low initially and gradually increased, depending on the clinical response (Table 4) and side effects. The decision to increase the dose, change...
The response of patients to treatment requires systematic monitoring. A practical set of criteria include nonresponse, a decrease in baseline severity of 25 percent or less; partial response, a 26 to 49 percent decrease in baseline severity; partial remission, a 50 percent or greater decrease in baseline severity (residual symptoms); and remission, an absence of symptoms. Options for the evaluation of the response include rating scales (Table 4) and the global judgment of the treating clinician on the basis of patient and family reports. The best predictors of outcome are improvements in anhedonia (loss of pleasure), psychomotor retardation, and loss of interest, which are assessed by asking questions that go beyond “depressed mood.” Suicidal ideation or risk of suicide, pessimism, guilt, and other changes in cognition may take longer to improve than vegetative symptoms, such as alterations in sleep or appetite. If initial treatment is not tolerated or the response is unsatisfactory (<50 percent improvement), a change in medication or approach is indicated. Thirty to 50 percent of patients have substantial residual symptoms after adequate first-line treatment (Table 3). If there has been no improvement after four weeks of treat-

Table 3. Selection of a First-Line Antidepressant Medication. *

<table>
<thead>
<tr>
<th>Variable</th>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age group</td>
<td></td>
</tr>
<tr>
<td>Children and adolescents</td>
<td>SSRI (fluoxetine)</td>
</tr>
<tr>
<td>Adults &lt;65 yr</td>
<td>SSRI, NRI, or SNRI</td>
</tr>
<tr>
<td>Adults ≥65 yr</td>
<td>SRI</td>
</tr>
<tr>
<td>Family history of response</td>
<td>Same medication that was effective in first-degree relative</td>
</tr>
<tr>
<td>Past response</td>
<td>Same medication that was effective previously</td>
</tr>
<tr>
<td>Depression characteristic</td>
<td></td>
</tr>
<tr>
<td>Bipolar depression</td>
<td>Mood stabilizer (lithium or lamotrigine) plus antidepressant</td>
</tr>
<tr>
<td>Psychotic depression</td>
<td>Antidepressant plus antipsychotic (atypical)</td>
</tr>
<tr>
<td>Depression with features of obsessive-compulsive disorder</td>
<td>SSRI</td>
</tr>
<tr>
<td>Panic attacks</td>
<td>SSRI</td>
</tr>
<tr>
<td>Agitated depression</td>
<td>Sedating antidepressant</td>
</tr>
<tr>
<td>Depression with psychomotor retardation</td>
<td>Nonsedating antidepressant (NRI, SSRI)</td>
</tr>
<tr>
<td>Medication-resistant depression</td>
<td>Electroconvulsive therapy or combination of medications</td>
</tr>
<tr>
<td>Coexisting medical conditions</td>
<td></td>
</tr>
<tr>
<td>Heart disease</td>
<td>Nontricyclic antidepressants</td>
</tr>
<tr>
<td>Stroke</td>
<td>Caution with SNRIs or NRIs and blood pressure</td>
</tr>
<tr>
<td>Pain</td>
<td>Duloxetine, venlafaxine</td>
</tr>
<tr>
<td>Concern regarding side effects</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal symptoms</td>
<td>Nontricyclic antidepressant</td>
</tr>
<tr>
<td>Anticholinergic symptoms</td>
<td>Nontricyclic antidepressant</td>
</tr>
<tr>
<td>Sexual dysfunction</td>
<td>Non-SSRI antidepressant</td>
</tr>
<tr>
<td>Weight gain</td>
<td>Avoid atypical antipsychotics</td>
</tr>
<tr>
<td>Postural hypotension</td>
<td>NRI</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Avoid atypical antipsychotics</td>
</tr>
</tbody>
</table>

Drug Therapy

Among patients receiving the same dose of a given drug, blood levels may vary by as much as a factor of 20 because of individual variations in drug metabolism. Such variations are caused by genetic differences, the effects of drugs on liver enzymes, and the effects of aging. Before medications are switched, consideration should be given to the diagnosis, the medication dose, and adherence to the drug regimen. Coexisting medical conditions, alcoholism, substance-use disorder, or the use of nonpsychiatric medications such as beta-blockers may also underlie treatment failures.

Nonresponse to medication requires a treatment change (Fig. 2). Switching to an antidepressant from a different pharmacologic class minimizes polypharmacy and reduces the risk of adverse drug interactions and side effects seen with combinations of similar drugs. The disadvantage of switching agents may be the loss of a possible partial response from the initial drug and a delay in the onset of antidepressant action from the second. The initial medication may need to be tapered to avoid symptoms of discontinuation, such as nausea, headache, and sensory changes. Switching from irreversible MAOIs to most other agents requires a minimum drug-free period of two weeks.

Switching to a new antidepressant from the same pharmacologic class is one option. Patients who do not have a response to one SSRI have a 40 to 70 percent chance of having a response to a second SSRI. Another approach is the use of two antidepressants from different classes with complementary mechanisms of action to avoid loss of a partial response to the first medication. This approach increases the risk of drug interactions and new side effects, as well as the cost of treatment.

Augmenting antidepressant medication with other agents, so-called augmenting agents, that may enhance antidepressant efficacy avoids the transition from the first to the second antidepressant and builds on partial remission. Lithium is a first-line augmenting agent. Two to four weeks of lithium treatment are needed before the response can be assessed. Lamotrigine is an effective augmenting agent for patients who do not have an adequate response to fluoxetine. Antipsychotic agents may augment the response in nonpsychotic major depression. Thyroid supplements have been advocated even in the absence of clinical hypothyroidism for the purpose of enhancing antidepressant action. Modafinil is a stimulant and as an adjunct may alleviate residual sleepiness and fatigue.

Mood disorders with delusions or hallucinations respond better to an antidepressant–antipsychotic combination than to either alone. Some patients with this constellation of symptoms will require electroconvulsive therapy (ECT), and almost all must be treated initially as inpatients.

Benzodiazepines are used as an adjunct for anxiety and insomnia in 30 to 60 percent of cases, and in that group improve response and reduce the frequency of treatment discontinuation. However, the drugs cause sedation, psychomotor and cognitive impairment, memory loss, and dependence and withdrawal syndromes and are associated with increased rates of falls, fractures, traffic accidents, and death among the elderly. The adjunctive use of benzodiazepines should be of limited duration to avoid dependence, and these drugs should be used with caution in the elderly and those with a history of alcohol or drug abuse or dependency.

Continuation Phase

The continuation phase of treatment, generally lasting six to nine months after the induction of remission, aims to eliminate residual symptoms, restore the prior level of functioning, and prevent recurrence or early relapse. Residual symptoms (partial remission) are strong predictors of recurrence, early relapse, or a more chronic future course. Treatment should continue until such symptoms have resolved. Episodes lasting more
Discontinuation of Treatment
If there is no recurrence or relapse during continuation therapy, gradual discontinuation may be planned for most patients after at least six months of treatment. Early discontinuation is associated with a 77 percent higher risk of relapse as compared with continuation treatment. The tapering of medication over several weeks also permits detection of returning symptoms that require reinstitution of a full medication dose for another three to six months. It also minimizes the discontinuation syndrome, which otherwise may last days or longer and consists of physical symptoms of imbalance, gastrointestinal and influenza-like symptoms, and sensory and sleep disturbances, as well as psychological symptoms such as anxiety, agitation, crying spells, and irritability. The discontinuation syndrome is sometimes called the withdrawal syndrome, erroneously implying drug dependence.

Maintenance Phase
Maintenance treatment for 12 to 36 months reduces the risk of recurrence by two thirds. This approach is indicated for patients with episodes that occur yearly, who have impairment because of mild residual symptoms, who have chronic major depression or dysthymia, or who have extremely severe episodes with a high risk of suicide. The duration of maintenance treatment will depend on the natural history of the illness and may be prolonged or indefinite in the case of recurrent illness.

The first choice of medication for the maintenance phase is the antidepressant that brought about remission. Lithium has no advantage over antidepressants for prophylaxis but may reduce the risk of suicide independently of its effect on mood. Tricyclic antidepressants, SSRIs, MAOIs, and the newer antidepressants (mirtazapine and venlafaxine) all help to prevent recurrence. Medication tolerability is particularly important during the maintenance phase, because it affects patients’ adherence to treatment. Stable patients should see a psychopharmacologist at intervals of three to six months while they are receiving medication. It is important to monitor adherence and breakthrough symptoms so that problems are detected early. Patient and family education reduces treatment attrition and improves the outcome.

Nonpharmacologic Therapies

ECT
Remission rates with ECT are 60 to 80 percent in severe major depressive disorder, though lower success rates are reported in community settings. The maximum response is typically achieved within three weeks. ECT can be a first-line treatment for patients who have severe major depressive disorder with psychotic features, psychomotor retardation, or medication resistance. ECT offers rapid relief for patients who are suicidal or pregnant. A course of ECT usually consists of 6 to 12 treatments, rarely exceeds 20 treatments, and is administered two or three times a week, preferably by an experienced psychiatrist. Side effects include transient postictal confusion and anterograde and retrograde memory impairment; the latter generally improves in days or weeks. After ECT, it is important to start prophylactic treatment with an antidepressant medication combined with an augmenting medication such as lithium, because the relapse rate is more than 50 percent.

Psychotherapy
Brief, structured psychotherapy techniques — such as cognitive behavioral therapy, interpersonal therapy, and certain problem-solving therapies — appear to be effective in acute-phase treatment and to delay relapse during continuation treatment of mild to moderately severe depression. Psychotherapy can be a first-line therapy for mild depression but not for severe depression, particularly psychotic and bipolar forms, unless used in combination with pharmacology. A combination of pharmacotherapy and psychotherapy may improve the treatment response, reduce the risk of a relapse, enhance the quality of life, and increase adherence to pharmacotherapy. Psychotherapy should be considered when substantial psychosocial stressors, interpersonal difficulties, or coexisting developmental or personality disorders are present.

Special Patient Populations

Patients with Bipolar Disorder
Depression in bipolar disorder carries the risk of a switch into mania. Mood stabilizers with antidepressant properties, such as lithium and l-
motrigine, help prevent mania, hypomania, and mixed or rapid-cycling states and are recommended as initial treatments of bipolar depression. For severe bipolar depression, a combination of an antidepressant (an SSRI or bupropion) and a mood stabilizer should be considered from the outset. The atypical antipsychotic drugs olanzapine and risperidone have antidepressant and antimanic effects but are more effective when combined with an antidepressant. The American Psychiatric Association recommends maintenance treatment after a single manic episode.

**CHILDREN AND ADOLESCENTS**

Fluoxetine is the only antidepressant with demonstrated efficacy in childhood and adolescent depression; other SSRIs, tricyclic agents, and other new-generation antidepressants have not been shown to be effective for depression in this age group. Fluoxetine is the only SSRI currently approved for pediatric use.

Rates of spontaneously reported suicidal ideaon and suicide attempts have been higher among depressed children and adolescents receiving antidepressants than among those receiving placebo in controlled clinical trials, but no differences were noted on weekly ratings of suicidality. This possible risk needs to be weighed against the risk of untreated depression, the most common cause of suicide in youth. There is an FDA black-box warning urging clinicians to monitor suicide risk and side effects very carefully when using antidepressants in youth (www.fda.gov/CDER/drug/antidepressants/default.htm).

**PREGNANT WOMEN**

Antidepressant medication should be considered for pregnant women in whom a moderately severe major depressive disorder develops spontaneously, as well as for those at high risk for recurrence if their medication is discontinued. Risks and benefits vary greatly among patients. Many antidepressants are transmitted in breast milk, and their use is reviewed elsewhere.

**REFERENCES**


**SUMMARY**

Major depression and bipolar disorder are generally recurrent episodic disorders. Antidepressant and adjunctive medications can successfully treat depression and prevent future episodes.

Future challenges include the identification of antidepressants that act more quickly than those currently available, which take six to eight weeks to achieve remission or substantial improvement, and that do not require continuation and maintenance treatment. A biologic classification system of subtypes of major depression is needed to facilitate the selection of the best antidepressant for each patient.

Supported by Public Health Service grants (MH48514 and MH40695) and the Stanley Medical Research Institute.

I am indebted to Dr. Dianne Currier for her research and assistance in the preparation of the manuscript.


42. Treatment for Adolescents with Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-20.

43. Mulder RT, Atkins WG, Joyce PB, Lucy SE. Age may affect response to antidepressants with serotonergic and noradrenergic actions. J Affect Disord 2003;76:143-9.


comes in the management of treatment re-
sistant depression: a focus on atypical anti-
psychotics. Bipolar Disord 2003;5:Suppl 2:36-
47.
78. Keck PE Jr. Bipolar depression: a new
role for atypical antipsychotics? Bipolar Dis-
79. Cohen D. Atypical antipsychotics and
new onset diabetes mellitus: an overview of
the literature. Pharmacopsychiatry 2004;37:
1-11.
80. Ananth J, Parmeswaran S, Gunatilake
S. Side effects of atypical antipsychotic
Clinical results for patients with major de-
pression disorder in the Texas Medication
Algorithm Project. Arch Gen Psychiatry 2004;
61:669-80.
82. Adli M, Berghofer A, Linden M, et al. Ef-
ficacy and feasibility of a standardized
stepwise drug treatment regimen algorithm for
inpatients with depressive disorders: results
of a 2-year observational algorithm study.
83. Hawley CJ, Pattinson HA, Quick SJ, et al.
A protocol for the pharmacoepidemiologic
study of major depression: a field test of a
potential prototype. J Affect Disord 1998;47:
87-96.
84. Swenson JR, O’Connor CM, Barton D,
et al. Influence of depression and effect of
treatment with sertraline on quality of life
after hospitalization for acute coronary syn-
85. Katona C. Managing depression and
anxiety in the elderly patient. Eur Neuro psy-
86. Greco T, Eckert G, Kroenke K. The out-
come of physical symptoms with treatment of
depression. J Gen Intern Med 2004;19:
813-8.
87. Amsterdam JD, Maislin G, Potter L. Flu-
oxetine efficacy in treatment resistant de-
pression. Prog Neuropsychopharmacol Biol
88. Rush AJ, Kupfer DJ. Strategies and tact-
cies in the treatment of depression. In: Gab-
bard GO, ed. Treatment of psychiatric dis-
89. Rothermundt C, de Montigny C, lithium
augmentation in treatment-resistant depres-
sion: a prospective multicenter study of
1022 outpatients. J Clin Psychiatry 2001;62:
90. Guelfi JD, Ansseau M, Timmerman L,
Korsgaard S. Mirtazapine versus venlafax-
ine in hospitalized severely depressed pa-
tients with melancholic features. J Clin Psy-
91. Feiger A, Kiefer A, Shirvastava RK, Wisse-
link PG, Wilcox CS. Nefazodone versus ser-
traline in outpatients with major depression:
focus on efficacy, tolerability, and effects on
sexual function and satisfaction. J Clin Psy-
double-blind, placebo-controlled trial of
divalproex and lithium in the treatment of
patients hospitalized for major depression.
93. Taylor FB, Prather MR. The efficacy of
nefazodone augmentation for treatment-
resistant depression with anxiety symptoms
or anxiety disorder. Depress Anxiety 2003;
94. Goodwin FK, Jamison KR. Manic-depres-
sive illness. New York: Oxford Univer-
95. Bauer M, Dorfner S. Lithium augmenta-
tion in treatment-resistant depression: meta-
analysis of placebo-controlled studies.
96. de Montigny C. Lithium addition for
the treatment of postpartum de-
pression. Arch Women Ment Health 2005;8:
55-6.
A double-blind, placebo-controlled trial of
nefazodone in the treatment of patients
hospitalized for major depression. J Clin Psy-
98. Thies-Flechtner K, Muller-Oerling-
hausen B, Seibert W, Walther A, Greil W.
Effect of prophylactic treatment on suicide
risk in patients with major affective disor-
der: data from a randomized prospective
99. Montgomery SA, Reimtz PE, Zirkov M.
Mirtazapine versus amitriptyline in the
long-term treatment of depression: a dou-
ble-blind placebo-controlled study. Int Clin
100. Simon JS, Aguilar LM, Kunz NR, Lei D.
Extended-release venlafaxine in relapse pre-
vention for patients with major depressive
disorder. J Clin Psychiatry 2004;65:
55-6.
101. Kupfer DJ, Grunhaus B, Link PG, Wil-
cox CS. Nefazodone versus sertraline in
the treatment of depression in the elderly.
102. Does incomplete recovery from first
lifetime major depressive episode herald a
chronic course of illness? Am J Psychiatry
103. Melki CA, Chawla AJ, Croghan TW,
Hanna MP, Kennedy S, Sredl K. The effects
of adherence to antidepressant treatment
guidelines on relapse and recurrence of
depression. Arch Gen Psychiatry 1998;55:
1128-32.
104. Schatzberg AF, Haddad P, Kaplan EM,
et al. Serotonin reuptake inhibitor discontinu-
ation syndrome: a hypothetical definition.
Relapse prevention with antidepressant drug
treatment in depressive disorders: a system-
106. Thies-Flechtner K, Muller-Oerling-
hausen B, Seibert W, Walther A, Greil W.
Effect of prophylactic treatment on suicide
risk in patients with major affective disor-
der: data from a randomized prospective
107. Montgomery SA, Reimtz PE, Zirkov M.
Mirtazapine versus amitriptyline in the
long-term treatment of depression: a dou-
ble-blind placebo-controlled study. Int Clin
108. Simon JS, Aguilar LM, Kunz NR, Lei D.
Extended-release venlafaxine in relapse pre-
vention for patients with major depressive
Drug therapy in the prevention of recurrenc-
es in unipolar and bipolar affective disor-
ders: report of the NIMH Collaborative
Study Group comparing lithium carbonate,
imipramine, and a lithium carbonate-impi-
ramine combination. Arch Gen Psychiatry
1984;41:1096-104.
111. UK ECT Review Group. Efficacy and
safety of electroconvulsive therapy in de-
pressive disorders: a systematic review and
112. Prudic J, Olsson M, Marcus SC, Fuller
RB, Sackeim HA. Effectiveness of electro-
convulsive therapy in community settings.
113. Nobler MS, Sackeim HA. Electrocon-
vulsive therapy. In: Henn F,
DRUG THERAPY


Copyright © 2005 Massachusetts Medical Society.

CLINICAL TRIAL REGISTRATION

The Journal encourages investigators to register their clinical trials in a public trials registry. The members of the International Committee of Medical Journal Editors plan to consider clinical trials for publication only if they have been registered (see N Engl J Med 2004;351:1250-1). The National Library of Medicine’s www.clinicaltrials.gov is a free registry, open to all investigators, that meets the committee’s requirements.